clinical trial · NCT04174365
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase3·completed·n = 119
Irritability Associated With Autism Spectrum Disorder (ASD)BrexpiprazolePlacebo
brief summary
The purpose of this study is to find out about the potential benefits and safety of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.
started
Oct 30, 2019
primary completion
Aug 8, 2022
completion
Sep 9, 2022
last updated
Aug 28, 2025
official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol